Core Insights - Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - During the second quarter 2025 earnings call, BellRing disclosed that certain customers are optimizing their inventories, leading to a slowdown in sales growth projected for the third quarter to low-single-digits [3] - Following the earnings call, BellRing's stock price dropped by $14.88 per share, or 18.97%, closing at $63.55 on May 6, 2025 [3] Company Overview - BellRing Brands, Inc. is publicly traded on the NYSE under the ticker BRBR [1] - The company is facing scrutiny due to claims of potential securities fraud, which may impact investor confidence and stock performance [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past, indicating a strong track record in handling such cases [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Gilead Sciences, Inc. and its officers or directors [1] Company Developments - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns related to decreases in CD4+ T-cell and absolute lymphocyte counts in trial participants [3] - Following the announcement of the clinical hold, Gilead's stock price decreased by $2.91, or 2.58%, closing at $110.09 per share on the same day [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Group 1 - A class action lawsuit has been filed against Reckitt Benckiser Group Plc for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Reckitt securities during the Class Period have until August 4, 2025, to request appointment as Lead Plaintiff [2] - Reckitt's American Depositary Share (ADS) price experienced significant declines following jury verdicts related to its subsidiary Mead Johnson's negligence in warning about health risks associated with its products [4][5] Group 2 - On March 15, 2024, an Illinois jury awarded $60 million against Reckitt's Mead Johnson subsidiary for failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants, leading to a nearly 14% drop in Reckitt's ADS price [4] - A subsequent lawsuit against Abbott Laboratories resulted in a $495 million award, similarly impacting Reckitt's ADS price with a nearly 9% decline [5] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [6]

Group 1 - The investigation by Pomerantz LLP concerns potential securities fraud or unlawful business practices by Vera Bradley and its officers or directors [1] - Vera Bradley reported disappointing financial results for Q1 of fiscal year 2026, with CEO Jackie Ardrey acknowledging the need for significant improvements to achieve positive growth [3] - Following the announcement of poor financial results, Vera Bradley's stock price dropped by $0.45, or 19.15%, closing at $1.90 per share on June 11, 2025 [4] Group 2 - Vera Bradley announced key leadership changes, including the departure of CEO Jackie Ardrey at the end of July 2025 [3]

Core Viewpoint - Centene Corporation is facing an investigation regarding potential securities fraud and unlawful business practices following its withdrawal of earnings guidance due to disappointing market growth and higher-than-expected health risks [1][3]. Group 1: Company Performance - On July 1, 2025, Centene announced the withdrawal of its 2025 GAAP and adjusted diluted earnings per share (EPS) guidance, citing that market growth in 22 out of 29 states was not meeting expectations [3]. - The company indicated that the overall health risks in these states were significantly higher than anticipated, impacting its risk adjustment revenue calculations [3]. Group 2: Market Reaction - Following the announcement, Centene's stock price experienced a significant decline, falling by $22.87 per share, or 40.37%, closing at $33.78 per share on July 2, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Centene investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from January 14, 2021, to June 5, 2025, seeking damages for misleading statements regarding the company's business and financial performance [1][8]. Company Overview - Petco is a specialty retailer offering a variety of pet products and services, including consumable and non-consumable products, as well as in-store veterinary and grooming services [4]. - A key business metric for Petco is comparable sales, which measures the change in period-over-period net sales from physical locations and digital sites [4]. Financial Performance and Misrepresentation - Petco claimed to benefit from pandemic-related tailwinds, including increased pet adoption rates, and positioned itself as a health-focused pet company capitalizing on trends of "pet humanization" and "premiumization" [5]. - However, as these pandemic-related tailwinds diminished, Petco's sales and profitability metrics began to decline significantly, with a notable downturn in mid-2023 [6]. - Despite worsening financial conditions, Petco's management continued to affirm optimistic financial guidance for FY 2023, including adjusted EBITDA of $520 million to $540 million and adjusted EPS of $0.40 to $0.48 [7]. Class Action Allegations - The complaint alleges that Petco's management made materially false and misleading statements about the sustainability of its business model and the strength of its product strategy, which were overstated [8]. - Specific allegations include the unsustainability of pandemic-related tailwinds, downplaying the severity of issues affecting sales, and overstating the company's ability to deliver sustainable growth [8]. Recent Financial Disclosures - On August 24, 2023, Petco revised its FY 2023 adjusted EBITDA guidance down to $460 million to $480 million and adjusted EPS to $0.24 to $0.30, leading to a 20.64% drop in stock price [9][10]. - Further negative revisions were made on November 29, 2023, with adjusted EBITDA guidance lowered to approximately $400 million and adjusted EPS to approximately $0.08, resulting in a 28.91% decline in stock price [11][12]. - In March 2024, Petco reported a GAAP net loss of $1.3 billion and acknowledged that its premium product-focused business model was not sustainable [13]. Market Reaction - Following the negative financial disclosures, Petco's stock price experienced significant declines, including a drop to $2.06 per share after the March 2024 results [14]. - On June 5, 2025, Petco reported a 1.3% year-over-year decline in comparable sales, larger than Wall Street estimates, leading to a further 23.2% drop in stock price [17][18].

Core Viewpoint - National Grid plc is under investigation for potential securities fraud and unlawful business practices following a fire incident at Heathrow Airport linked to its electrical substation [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of investors of National Grid, focusing on possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation is prompted by a report from the National Energy System Operator (NESO) indicating that National Grid was aware of a fault at an electrical substation since 2018 but failed to address it, leading to a fire that caused Heathrow Airport to shut down [3]. Group 2: Market Reaction - Following the news of the investigation and the fire incident, National Grid's American Depositary Receipt (ADR) price dropped by $3.77, or 5.07%, closing at $70.61 per ADR on July 2, 2025 [4].

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...